Literature DB >> 21052918

Acquired resistance to infliximab against uveitis due to Behçet's disease after one year of administration.

Takako Ito, Koh-Hei Sonoda, Kuniaki Hijioka, Takeshi Fujimoto, Tatsuro Ishibashi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21052918     DOI： 10.1007/s10384-010-0859-0

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN： 0021-5155            Impact factor:   2.447


× No keyword cloud information.
  4 in total

1.  Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial.

Authors:  Richard J Farrell; Mazen Alsahli; Yoon-Tae Jeen; Kenneth R Falchuk; Mark A Peppercorn; Pierre Michetti
Journal:  Gastroenterology       Date:  2003-04       Impact factor: 22.682

2.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Authors:  P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

3.  Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis.

Authors:  Shigeaki Ohno; Satoshi Nakamura; Sadao Hori; Machiko Shimakawa; Hidetoshi Kawashima; Manabu Mochizuki; Sunao Sugita; Satoki Ueno; Kazuyuki Yoshizaki; Goro Inaba
Journal:  J Rheumatol       Date:  2004-07       Impact factor: 4.666

4.  Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study.

Authors:  Tsutomu Takeuchi; Nobuyuki Miyasaka; Kazuhiko Inoue; Tohru Abe; Takao Koike
Journal:  Mod Rheumatol       Date:  2009-07-22       Impact factor: 3.023
  4 in total
  3 in total

1.  Long-term efficacy of infliximab treatment and the predictors of treatment outcomes in patients with refractory uveitis associated with Behçet's disease.

Authors:  Sho Ueda; Mitsuteru Akahoshi; Atsunobu Takeda; Yasushi Inoue; Aya Omoto; Masahiro Ayano; Yasutaka Kimoto; Hiroki Mitoma; Yojiro Arinobu; Hiroaki Niiro; Hiroshi Tsukamoto; Takahiko Horiuchi; Shin-Ichi Hikita; Takako Fukuhara; Tatsuro Ishibashi; Koh-Hei Sonoda; Koichi Akashi
Journal:  Eur J Rheumatol       Date:  2018-03

2.  Long-term efficacy of infliximab on background vascular leakage in patients with Behçet's disease.

Authors:  H Keino; A A Okada; T Watanabe; W Taki
Journal:  Eye (Lond)       Date:  2014-06-20       Impact factor: 3.775

3.  Psoriasis triggered by infliximab in a patient with Behçet's disease.

Authors:  Yuko Kawazoe; Sunao Sugita; Yukiko Yamada; Ai Akino; Keiko Miura; Manabu Mochizuki
Journal:  Jpn J Ophthalmol       Date:  2012-10-23       Impact factor: 2.447
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.